2023
DOI: 10.3389/fphar.2023.1176443
|View full text |Cite
|
Sign up to set email alerts
|

The Chinese herbal medicine Dai-Zong-Fang promotes browning of white adipocytes in vivo and in vitro by activating PKA pathway to ameliorate obesity

Abstract: Introduction: The global prevalence of obesity is rising rapidly. Conversion of white adipose tissue (WAT) into beige adipose tissue with heat-consuming characteristics, i.e., WAT browning, effectively inhibits obesity. Dai-Zong-Fang (DZF), a traditional Chinese medicine formula, has long been used to treat metabolic syndrome and obesity. This study aimed to explore the pharmacological mechanism of DZF against obesity.Methods:In vivo, C57BL/6J mice were fed high-fat diets to establish the diet-induced obese (D… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 60 publications
0
3
0
Order By: Relevance
“…DZF extract (freeze-dried powder) was produced and supplied by Zhejiang Jiu Xu Pharmaceutical Co., LTD. (Batch Number: YC20200501). The extraction method and quality control are detailed in the Chinese patent document titled “A Traditional Chinese Medicine Composition and Its Preparation for Treating Metabolic Syndrome” (Chinese Patent No: ZL201811080557.5) ( Xu et al, 2023 ). High-performance liquid chromatography (HPLC) was used to determine the major active chemical components in DZF, including berberine, naringin, hesperidin, and lovastatin ( Zhu et al, 2018 ).…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…DZF extract (freeze-dried powder) was produced and supplied by Zhejiang Jiu Xu Pharmaceutical Co., LTD. (Batch Number: YC20200501). The extraction method and quality control are detailed in the Chinese patent document titled “A Traditional Chinese Medicine Composition and Its Preparation for Treating Metabolic Syndrome” (Chinese Patent No: ZL201811080557.5) ( Xu et al, 2023 ). High-performance liquid chromatography (HPLC) was used to determine the major active chemical components in DZF, including berberine, naringin, hesperidin, and lovastatin ( Zhu et al, 2018 ).…”
Section: Methodsmentioning
confidence: 99%
“…Furthermore, more in-depth research indicates that after intervention with DZF in mice subjected to diet-induced obesity C57BL/6J mice and db/db mice, it mitigates insulin resistance and disturbances in glucose and lipid metabolism ( Zhu et al, 2018 ; Huang et al, 2022a ). Additionally, DZF promotes browning of white adipocytes both in vitro and in vivo ( Xu et al, 2023 ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Obesity accumulates excessive amount of white adipose tissues (WAT) in the body which means imbalance between expenditure and energy storage (Xu et al, 2023). It is also associated with various medical health conditions for every age of human being due to several risk factors such as genetic disorders, a sedentary lifestyle, bad food habits, and lack of physical activity (Romagnolli et al, 2020;WHO.…”
Section: Introductionmentioning
confidence: 99%